tretazicar has been researched along with Carcinoma 256, Walker in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burke, PJ; Chen, S; Kerr, DJ; Knox, RJ | 1 |
| Biggs, PJ; Davies, L; Flitter, WD; Friedlos, F; Gaskell, M; Goddard, P; Jarman, M; Knox, RJ | 1 |
| Boland, MP; Friedlos, F; Knox, RJ | 1 |
| Boland, MP; Davies, LC; Friedlos, F; Jarman, M; Knox, RJ | 1 |
| Sugget, N; Walton, MI; Workman, P | 1 |
| Boland, MP; Coles, B; Friedlos, F; Knox, RJ; Roberts, JJ; Southan, C | 1 |
| Friedlos, F; Jarman, M; Knox, RJ; Roberts, JJ | 1 |
| Friedlos, F; Knox, RJ; Roberts, JJ | 1 |
2 review(s) available for tretazicar and Carcinoma 256, Walker
| Article | Year |
|---|---|
CB 1954: from the Walker tumor to NQO2 and VDEPT.
Topics: Animals; Antineoplastic Agents; Aziridines; Carcinoma 256, Walker; Cell Survival; Escherichia coli; Genetic Therapy; Humans; Nitroreductases; Prodrugs; Quinone Reductases; Rats; Tumor Cells, Cultured | 2003 |
The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).
Topics: Animals; Antineoplastic Agents; Aziridines; Biotransformation; Carcinoma 256, Walker; Cell Line; Cell Survival; DNA; Drug Carriers; Humans; Mice; Prodrugs; Tumor Cells, Cultured | 1993 |
6 other study(ies) available for tretazicar and Carcinoma 256, Walker
| Article | Year |
|---|---|
Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzamides; Carcinoma 256, Walker; Cell Line; Cricetinae; Cricetulus; Cross-Linking Reagents; Mice; Mice, Inbred BALB C; Plasmacytoma; Prodrugs; Rats | 1993 |
Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2).
Topics: Animals; Aziridines; Carcinoma 256, Walker; Coenzymes; Kinetics; NAD(P)H Dehydrogenase (Quinone); NADP; Niacinamide; Nicotinamide Mononucleotide; Oxidation-Reduction; Pyridinium Compounds; Rats; Structure-Activity Relationship; Vitamin K | 1992 |
The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
Topics: Animals; Antineoplastic Agents; Aziridines; Carcinoma 256, Walker; Cell Hypoxia; Colonic Neoplasms; Humans; In Vitro Techniques; Indolequinones; Indoles; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Prodrugs; Rats; Tirapazamine; Triazines | 1992 |
The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Aziridines; Azirines; Biotransformation; Carcinoma 256, Walker; Molecular Sequence Data; NAD(P)H Dehydrogenase (Quinone); Nitroreductases; Oxidoreductases; Quinone Reductases; Spectrophotometry, Ultraviolet | 1988 |
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Carcinoma 256, Walker; Cell Survival; Cricetinae; Cross-Linking Reagents; DNA Damage; NAD; Nitroreductases; Oxidoreductases; Rats; Tumor Cells, Cultured | 1988 |
CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Carcinoma 256, Walker; Cell Survival; Cricetinae; Cricetulus; Cross-Linking Reagents; DNA, Neoplasm; In Vitro Techniques; Rats | 1986 |